At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer Who Have Failed at Least Two Prior Therapies
In Brief
A Phase 2 clinical trial evaluating imatinib mesylate by mouth and Gemcitabine Intravenous for Ovarian Cancer and Primary Peritoneal Cancer. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment. Gleevec is an oral chemotherapy drug used is this study and Gemzar is an IV chemotherapy drug used. Participation in the treatment portion of the study will continue as long as the patient's tumors shrink or remain stable and as long as the patient is able to tolerate the study drug. The follow-up portion of the study will last for 5 years.
Study Details
Timeline
Interventions
imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle